Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FPP003 in adults with moderate to severe plaque psoriasis
ACTRN12619000599178Phase 2Completed
- Sponsor
- FunPep
- Start
- Apr 2019
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of FPP003 in plaque psoriasis (8 cohorts), sponsored by FunPep. Primary endpoint: Safety and tolerability of escalating doses of FPP003 versus placebo. Started Apr 2019; status: completed.
02
Drugs
FPP003
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ACTRN12619000599178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000599178.